
Valneva SE (VALN) Stock Forecast & Price Target
Valneva SE (VALN) Analyst Ratings
Bulls say
Valneva SE has modestly increased its assumptions for the commercial uptake of the Lyme vaccine candidate VLA15 in Europe, aligning more closely with higher uptake expectations in the U.S., indicating a positive trend for future revenue generation. Recent reports of strong immune responses following a third yearly booster of VLA15 in both adults and children further bolster the company's potential market position and attractiveness to pharmaceutical partners. Despite a temporary setback with the FDA regarding Ixchiq, the overall financial health remains stable, with earnings aligning with expectations and a focus on developing a robust pipeline of life-saving vaccines.
Bears say
Valneva SE faces significant financial risks stemming from clinical and regulatory setbacks that could adversely impact its revenue generation from marketed vaccines. Recent safety concerns regarding its Ixchiq vaccine have raised competitiveness issues against rival products, particularly Bavarian Nordic's chikungunya vaccine, limiting expected product uptake in Europe. Additionally, the removal of U.S. sales projections for Ixchiq further compounds the company's challenges, suggesting a further deterioration in potential cash flows from product sales.
This aggregate rating is based on analysts' research of Valneva SE and is not a guaranteed prediction by Public.com or investment advice.
Valneva SE (VALN) Analyst Forecast & Price Prediction
Start investing in Valneva SE (VALN)
Order type
Buy in
Order amount
Est. shares
0 shares